Artificial Insemination Market Size, Share & Trends Analysis Report By End Use (Home, Fertility Clinics & Other Facilities), By Type (Intrauterine, Intravaginal), By Source Type (AIH, AID), And Segment Forecasts, 2019 - 2026

Industry Insights

The global artificial insemination market size was valued at USD 1.5 billion in 2018 and is projected to expand at a CAGR of 8.4% over the forecast period. According to the WHO, around 10% of women are directly or indirectly affected by infertility. Also, the National Institutes of Health reported that infertility affects around 12% of couples of reproductive age.

The WHO monitors infertility prevalence across the globe in line with ‘WHO Reproductive Health Indicators, Guidelines for their generation, interpretation, and analysis for global monitoring’. According to the United Nations, the global fertility rate is expected to decline to 2.4% by 2030 and 2.2% by 2050. In some countries, including the U.S. and U.K., same-sex couples are provided insurance coverage for artificial insemination procedures.

As per the National Institute for Health and Clinical Excellence (NICE) guidelines, same-sex couples should be eligible to avail of fertility treatments. The NHS expects such couples to have undergone six cycles of self-funded artificial insemination to be able to avail NHS-funded fertility treatments. Artificial insemination is a first-line of infertility treatment, as it is minimally invasive and less expensive as compared to IVF. Intrauterine insemination held the majority of the market share in 2018 and is likely to be the fastest-growing segment over the forecast period as it is the most common and non-invasive procedure.

Fertility clinics held a majority of the market share in the year 2018 due to a higher number of medical facilities offering infertility treatments. Europe held a majority of the market share in the year 2018. North America was the second-largest market in 2018. Some of the key companies in the global artificial insemination market include Vitrolife; Genea Ltd.; Rinovum Women’s Health, LLC; Pride Angel; Hi-Tech Solutions; FUJIFILM Irvine Scientific; Kitazato Corp.; and Rocket Medical plc.

Type Insights

Intrauterine insemination held the majority of the market share in 2018 and is likely to retain its position. It is expected to be the fastest-growing segment over the forecast period. This mode of insemination is most preferred for infertility treatment as it provides the highest pregnancy rate. Also, it is a non-invasive technique. Intravaginal (IVI) is projected to be the second-largest segment. IVI can be performed at fertility clinics or home and is especially preferred in cases of surrogacy and donor insemination.

End-Use Insights

Fertility clinics held the largest market share in 2018 and are likely to be the fastest-growing end-use segment over the forecast period. The number of medical centers offering infertility treatment has increased over the past few years due to rising infertility rates across the world. All the types of artificial insemination procedures can be performed at fertility clinics.

Mostly, Intrauterine (IUI) and Intratubal (ITI) procedures are performed in fertility clinics. Insemination procedures at clinics involve consultation, which includes determination of the ovulation cycle before initiating the procedures. Also, doctors can prescribe fertility medications to increase the chances of conception.

Source Type Insights

Artificial Insemination by Husband (AIH) segment led the market. It is also expected to witness the fastest CAGR over the forecast period. Donor insemination (AID) opts as a last alternative by couples with non-viable sperm. Single women or same-sex couples can also choose AID. Donor insemination has proven to be safe as sperm banks are supposed to provide personal medical and extensive family histories of donors.

Regional Insights

Europe was the largest regional market in 2018 as the fertility rate in the region has been decreasing over the years. Delay in pregnancy and lifestyle changes are among the factors contributing to this decline. North America was the second-largest market. There were only 62.5 births per 1000 women, according to the National Center for Health Statistics. The Asia Pacific is expected to be the fastest-growing market in the forecast years due to the increasing infertility rate and raising awareness about the available treatment options.

Artificial Insemination Market Share Insights

Some of the key companies in the market are Vitrolife; Genea Limited; Rinovum Women’s Health, LLC; Pride Angel; Hi-Tech Solutions; FUJIFILM Irvine Scientific; KITAZATO CORPORATION; Rocket Medical plc. Companies focus on the acquisition of small firms to strengthen their presence in regional markets. For instance, in March 2018, JXTGE announced the sale of Irvine Scientific to FUJIFILM, which acquired the company to maximize its synergy and maintain its growth in the biomedical industry. The acquisition was completed in June 2018.

Report Scope

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For this study, Grand View Research has segmented the global artificial insemination market report based on type, end-use, source type, and region:

• Type Outlook (Revenue, USD Million, 2015 - 2026)

  • Intrauterine

  • Intracervical

  • Intravaginal

  • Intratubal

• End-Use Outlook (Revenue, USD Million, 2015 - 2026)

  • Fertility Clinics & Other Facilities

  • Home

• Source Type Outlook (Revenue, USD Million, 2015 - 2026)

  • AIH-Husband

  • AID-Donor

• Regional Outlook (Revenue, USD Million, 2015 - 2026)

  • North America

    • The U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa